Aberrant DNA methylation of PTPRG as one possible mechanism of its under‐expression in CML patients in the State of Qatar-Reference-Cited by-同舟云学术

Aberrant DNA methylation of PTPRG as one possible mechanism of its under‐expression in CML patients in the State of Qatar

Published:2020-07-23 Issue:10 Volume:8 Page:
ISSN:2324-9269
Container-title:Molecular Genetics & Genomic Medicine
language:en
Short-container-title:Mol Genet Genomic Med

Author:

Ismail Mohamed A.¹²^ORCID,Samara Muthanna³,Al Sayab Ali²,Alsharshani Mohamed⁴,Yassin Mohamed A.⁵,Varadharaj Govindarajulu⁶,Vezzalini Marzia⁷,Tomasello Luisa⁸,Monne Maria⁹,Morsi Hisham¹⁰,Qoronfleh M. Walid¹¹^ORCID,Zayed Hatem¹²,Cook Richard¹,Sorio Claudio⁷,Modjtahedi Helmout¹^ORCID,Al‐Dewik Nader I.¹¹³¹⁴¹⁵^ORCID

Affiliation:

1. School of Life Science, Pharmacy and Chemistry Faculty of Science, Engineering & ComputingFaculty of Science, Engineering & Computing Kingston University London Kingston‐Upon‐Thames UK

2. Interim Translational Research Institute (iTRI)Hamad Medical Corporation (HMC) Doha Qatar

3. Department of Psychology Kingston University London Kingston upon Thames, London UK

4. Diagnostic Genetics Division (DGD) Department of Laboratory Medicine and Pathology (DLMP) Hamad Medical Corporation (HMC) Doha Qatar

5. Department of Medical Oncology National Centre for Cancer Care and ResearchHamad Medical Corporation (HMC) Doha Qatar

6. Genetrics Inc Dubai United Arab Emirates

7. General Pathology Division Department of Medicine University of Verona Verona Italy

8. Wexner Medical Center Biomedical Research Tower The Ohio State University Columbus OH USA

9. Centro di Diagnostica Biomolecolare e Citogenetica Emato‐Oncologica San Francesco” Hospital Nuoro Italy

10. Quality of Life unit National Center for Cancer Care and Research, (NCCCR) Hamad Medical Corporation (HMC) Doha Qatar

11. World Innovation Summit for Healthcare (WISH) Qatar Foundation Doha Qatar

12. Department of Biomedical Sciences Biomedical Research CenterCollege of Health SciencesQU HealthQatar University Doha Qatar

13. Qatar Medical Genetic Center (QMGC) Hamad General Hospital (HGH)and Interim Translational Research Institute (iTRI)Hamad Medical Corporation (HMC) Doha Qatar

14. College of Health and Life Science (CHLS) Hamad Bin Khalifa University (HBKU) Doha Qatar

15. Department of Pediatrics Women's Wellness and Research Center (WWRC)HMC Doha Qatar

Funder

Qatar Foundation

Publisher

Wiley

Subject

Genetics(clinical),Genetics,Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mgg3.1319

Reference53 articles.

1. Current perspectives for the treatment of chronic myeloid leukemia;Aladag E.;Turkish Journal of Medical Sciences,2019

2. BCR‐ABL kinase point mutations don't correlate with the resistance of chronic myelocytic leukemia (CML) to imatinib mesylate (IM); A study on CML patient population in Qatar;Al‐Dewik N. I. E.;Hamad bin Khalifa University Press (HBKU Press),2011

3. Elevation of alpha acid glycoprotein (AGP) does not correlate with the resistance of chronic myeloid leukaemia (CML) to imatinib mesylate (IM);Al‐Dewik N. I. E.;Hamad bin Khalifa University Press (HBKU Press),2011

4. Studying the impact of presence of point mutation, insertion mutation and additional chromosomal abnormalities in chronic myeloid leukemia patients treated with imatinib mesylate in the State of Qatar

5. Molecular Monitoring of patients with Chronic Myeloid Leukemia (CML) in the state of Qatar: Optimization of Techniques and Response to Imatinib

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies;Hematology;2023-04-20

2. Gene Expression Landscape of Chronic Myeloid Leukemia K562 Cells Overexpressing the Tumor Suppressor Gene PTPRG;International Journal of Molecular Sciences;2022-08-31

3. Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors;Gene;2022-03

4. The Role of the Tumor Suppressor Gene Protein Tyrosine Phosphatase Gamma in Cancer;Frontiers in Cell and Developmental Biology;2022-01-05

5. Protein Tyrosine Phosphatase Receptor Gamma as Potential Therapeutic Target for Chronic Myeloid Leukemia Patients;Cancer Control;2022-01